Matthias Preusser on the phase 2 TUXEDO-3 trial
About this episode
Ali Landman interviews Matthias Preusser about the TUXEDO-3 trial and its implications for treating brain metastases in cancer patients.
Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer. Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is ...
More episodes of The Lancet Oncology in conversation with
- Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
- James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
- Ali Landman on the European Congress of Radiology 2026
- Kayleigh Bhangdia on breast cancer GBD study 2023
- Dylan Graetz and Erica Kaye on qualitative research in oncology
- Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
Explore listener stats, chart rankings, contacts and more on the The Lancet Oncology in conversation with podcast page.